Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Amarin Corporation plc

< Previous 1 2 3 Next >
Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Appoints JEC Capital Partners’ Michael Torok to Board of Directors
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Reports Fourth Quarter Financial Results & Business Update and Announces Important Corporate Action
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Receives National Reimbursement for VAZKEPA® in Austria
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Receives National Reimbursement for VAZKEPA® in Italy
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Appoints Peter Fishman Chief Financial Officer
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Announces Two Upcoming Investor Events
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR)
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Board of Directors Announces CEO Transition
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Reports First Quarter 2024 Business Update and Financial Results
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Announces Results of Annual General Meeting of Shareholders
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.